v3.26.1
Financial Instruments
12 Months Ended
Apr. 24, 2026
Investments [Abstract]  
Financial Instruments Financial Instruments
Debt Securities
The Company holds investments in marketable debt securities that are classified and accounted for as available-for-sale and are remeasured on a recurring basis. The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at April 24, 2026 and April 25, 2025:
April 24, 2026
ValuationBalance Sheet Classification
(in millions)CostUnrealized
Gains
Unrealized
Losses
Fair ValueInvestmentsOther Assets
Level 1:
U.S. government and agency securities$420 $— $(4)$416 $416 $— 
Level 2:
Corporate debt securities4,041 25 (15)4,050 4,050 — 
U.S. government and agency securities812 — (9)803 803 — 
Mortgage-backed securities852 (18)842 842 — 
Non-U.S. government and agency securities23 — — 23 23 — 
Other asset-backed securities1,121 (7)1,118 1,118 — 
Total Level 26,849 37 (49)6,837 6,837 — 
Level 3:
Auction rate securities36 — (2)34 — 34 
Total available-for-sale debt securities$7,305 $37 $(56)$7,287 $7,253 $34 
April 25, 2025
ValuationBalance Sheet Classification
(in millions)CostUnrealized
Gains
Unrealized
Losses
Fair ValueInvestmentsOther Assets
Level 1:
U.S. government and agency securities$417 $— $(7)$410 $410 $— 
Level 2:
Corporate debt securities3,540 17 (36)3,521 3,521 — 
U.S. government and agency securities835 — (20)814 814 — 
Mortgage-backed securities948 (29)923 923 — 
Non-U.S. government and agency securities— — — 
Other asset-backed securities1,044 (6)1,044 1,044 — 
Total Level 26,373 26 (91)6,308 6,308 — 
Level 3:
Auction rate securities36 — (3)33 — 33 
Total available-for-sale debt securities$6,826 $26 $(100)$6,752 $6,719 $33 
The amortized cost of debt securities excludes accrued interest, which is reported in other current assets in the consolidated balance sheets.
The following tables present the gross unrealized losses and fair values of the Company’s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at April 24, 2026 and April 25, 2025:
 April 24, 2026
 Less than 12 monthsMore than 12 months
(in millions)Fair ValueUnrealized
Losses
Fair ValueUnrealized
Losses
Corporate debt securities$653 $(3)$1,110 $(12)
U.S. government and agency securities313 (4)434 (9)
Mortgage-backed securities— — 335 (18)
Other asset-backed securities— — 440 (7)
Auction rate securities— — 34 (2)
Total$966 $(7)$2,353 $(48)
 April 25, 2025
 Less than 12 monthsMore than 12 months
(in millions)Fair ValueUnrealized
Losses
Fair ValueUnrealized
Losses
Corporate debt securities$702 $(7)$1,235 $(29)
U.S. government and agency securities110 (1)641 (25)
Mortgage-backed securities(1)614 (28)
Other asset-backed securities— — 469 (6)
Auction rate securities— — 33 (3)
Total$814 $(9)$2,993 $(91)

The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers into or out of Level 3 during fiscal years 2026 and 2025. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement.
Gains and losses on available-for-sale debt securities are recognized in other non-operating expense (income), net in the consolidated statements of income. During fiscal years 2026, 2025, and 2024, gross realized gains and losses on available-for-sale debt securities were not material. During fiscal years 2026, 2025 and 2024, proceeds from sales of available-for-sale debt securities were $8.0 billion, $8.2 billion, and $7.4 billion, respectively.
The contractual maturities of available-for-sale debt securities at April 24, 2026 are shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.
(in millions)Amortized CostFair Value
Due in one year or less$1,803 $1,796 
Due after one year through five years2,970 2,972 
Due after five years through ten years1,058 1,061 
Due after ten years1,474 1,458 
Total$7,305 $7,287 
Interest income, which includes income on marketable debt securities and the global liquidity structures, is recognized in other non-operating expense (income), net, in the consolidated statements of income. For fiscal years 2026, 2025, and 2024 there was $383 million, $511 million, and $597 million of interest income, respectively.
Equity Securities, Equity Method Investments, and Other Investments
The following table summarizes the Company's equity and other investments and related accrued interest receivable at April 24, 2026 and April 25, 2025, which are classified as primarily other assets in the consolidated balance sheets:
(in millions)April 24, 2026April 25, 2025
Investments with readily determinable fair value (marketable equity securities)$130 $17 
Investments for which the fair value option has been elected— 140 
Investments without readily determinable fair values616 705 
Equity method and other investments78 89 
Total equity and other investments$824 $951 
The table below includes activity related to the Company's portfolio of equity and other investments. The activity for fiscal year 2024 was not material. Gains and losses on equity and other investments are recognized in other non-operating expense (income), net in the consolidated statements of income.
Fiscal Year
(in millions)20262025
Proceeds from sales$139 $308 
Gross gains122 108 
Gross losses(182)(204)
Interest income35 — 
Impairment losses recognized(71)(135)
During fiscal year 2026, there were $150 million of net unrealized losses on equity securities and other investments still held at April 24, 2026. During fiscal year 2025, there were $181 million of net unrealized losses on equity securities and other investments still held at April 25, 2025.
Mozarc Medical Investment
As described in Note 3, in fiscal year 2023 the Company sold half its RCS business to Mozarc, and as a result of the transaction the Company retained a 50% non-controlling equity interest in Mozarc. This investment provides the Company with the ability to exercise significant influence over Mozarc and the Company has elected the fair value option to account for this equity method investment. The Company believes the fair value option best reflects the economics of the underlying transaction.
Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period in other non-operating expense (income), net in the consolidated statements of income. During fiscal years 2026, 2025, and 2024, the Company recognized a loss of $140 million, $171 million, and $220 million, respectively, reducing the fair value of the investment to zero as of the end of fiscal year 2026. The losses were primarily driven by historical financial results, the restructuring and wind-down of certain product lines, the delay or discontinuation of certain research and development programs and associated product launches, and projections of future cash flows.
The following table provides a reconciliation of the beginning and ending balances of the Mozarc investment for which the fair value option has been elected:
Fiscal Year
(in millions)20262025
Beginning balance$140 $311 
Additions— 
Settlements(7)— 
Change in fair value(140)(171)
Ending balance$— $140